131 Iodine-Tenatumomab

N/A

Report date: 2025/09/04 17:53:57

Base Information

Drug Name131 Iodine-Tenatumomab
Drug Alias Name131I-TenatumomabTenatumomab I 131Tenatumomab/ST2146
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineDiagnostic agent (In vivo) +[7
Mechanisms of Actionanti-Tenascin
TargetsTenascin
Therapy Area/IndicationsUrogenital NeoplasmsRespiratory Tract NeoplasmsSkin Neoplasms +[9
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSigma-Tau Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSigma-Tau Ifr Spa
Active IndicationsN/A
Inactive IndicationsUrogenital NeoplasmsRespiratory Tract NeoplasmsSkin Neoplasms +[9

Other Information

ATC CodeN/A
Related LinksDrugBank